News

Filter

Current filters:

AdvairGlaxoSmithKline

1 to 9 of 26 results

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay

11-10-2013

The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Great expectations for GlaxoSmithKline R&D newsflow

13-12-2012

Essentially, analysts at Panmure Gordon & Co anticipate a lot of pipeline newsflow from UK pharma giant…

AdvairdarapladibFinancialGlaxoSmithKlineMAGE-A3PharmaceuticalResearch

1 to 9 of 26 results

Back to top